Your session is about to expire
← Back to Search
CAR T-cell Therapy for Breast Cancer
This trial is testing a new way to treat breast cancer using a patient's own T cells that have been engineered to express a chimeric antigen receptor. This new treatment is specific for a cleaved form of MUC1.
- Metastatic Breast Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Your doctors think you have less than 3 months to live.You cannot take cyclophosphamide chemotherapy due to a medical reason.You have another type of cancer that is getting worse or needs treatment.You have low blood pressure that is causing health problems.You have severe heart problems that are causing symptoms and have not been brought under control.You have taken experimental medication(s) within the past 30 days before the planned lymphodepletion treatment.If you have hormone receptor positive disease, you must have already tried at least 3 different hormone therapies and 2 different chemotherapy treatments for your advanced cancer.
- Group 1: Luminal
- Group 2: Triple Negative
- Group 3: HER2+
- Group 4: Dose Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this investigation currently open to new participants?
"This clinical trial is open for enrollment, as indicated on the website of clinicaltrials.gov. This study was first announced on January 15th 2020 and recently modified in December 22nd 2021."
How many participants can the trial accommodate?
"Affirmative, according to the data on clinicaltrials.gov this study is still in need of participants. This medical trial was first posted on January 15th 2020 and last updated December 22nd 2021; 69 patients are being recruited from a single site."
Has the FDA approved huMNC2-CAR44 CAR T cells for therapeutic use?
"Given its status as a Phase 1 study, with limited data on efficacy and safety, the team at Power rates huMNC2-CAR44 CAR T cells' safety level at 1."
Share this study with friends